# Shanghai Henlius Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-henlius-biotech

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.henlius.com
- Total disclosed funding: $180M
- Latest round: Series B (Jul 19, 2018)
- Investors on record: 7

## About

Founded in 2010 and based in Shanghai, China, Shanghai Henlius Biotech, Inc. operates as a biopharmaceutical company that focuses on the research and development of antibody drugs and related products. It was recognized as the National High-tech Enterprise. Jun Zhu, the executive director and chief executive officer of the company, used to serve as the chief executive officer of Jiasheng China and the global vice president of IQVIA. The company's commercial production base and supporting quality management system have received GMP certification in China, the European Union, and the United States. It has 3 production base in Xuhui and Songjiang. The company established a branch office in Shanghai in 2017. In September 2019, the company was listed on the Hong Kong Exchanges and Clearing Limited.
Shanghai Henlius Biotech, Inc. mainly engages in the research, development, production, and sales of antibody drugs and related products. The company has conducted over 30 clinical studies for 16 products globally. It has a product pipeline of more than 20 innovative monoclonal antibody and tumor immunology combination therapy candidates, including HLX01, HLX02, HLX06, etc. Products can be used in the treatment of oncology, autoimmune diseases, ophthalmic diseases, and other diseases.

The company generates revenue by selling antibody drugs.

## Funding rounds

- Series B, Jul 19, 2018, $157M — China International Capital Corporation, Loyal Valley Capital, Green Tomato Limited, New China Capital, Fuguo Asset Management
- Series A, Jul 29, 2016, $19M — Huagai Capital
- Angel, Mar 20, 2016, $4M — Founder H Fund

## Investors

- Founder H Fund (https://capitalatlas.ai/funds/founder-h-fund) — Angel
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series B
- Green Tomato Limited — Series B
- New China Capital (https://capitalatlas.ai/funds/new-china-capital) — Series B
- Fuguo Asset Management — Series B